609 related articles for article (PubMed ID: 17332360)
21. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
22. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
25. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
[TBL] [Abstract][Full Text] [Related]
26. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Wang L; Qi X; Sun Y; Liang L; Ju D
Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
[TBL] [Abstract][Full Text] [Related]
28. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
31. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
[TBL] [Abstract][Full Text] [Related]
32. Combination gene therapy of IL-12 and allogeneic MHC class I gene via stimulating NK cytolytic activity.
Yoon SJ; Heo DS; Kang JO; Kim NK
Anticancer Res; 1999; 19(5B):4337-42. PubMed ID: 10628397
[TBL] [Abstract][Full Text] [Related]
33. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Pinthus JH; Waks T; Kaufman-Francis K; Schindler DG; Harmelin A; Kanety H; Ramon J; Eshhar Z
Cancer Res; 2003 May; 63(10):2470-6. PubMed ID: 12750268
[TBL] [Abstract][Full Text] [Related]
34. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
Siders WM; Wright PW; Hixon JA; Alvord WG; Back TC; Wiltrout RH; Fenton RG
J Immunol; 1998 Jun; 160(11):5465-74. PubMed ID: 9605149
[TBL] [Abstract][Full Text] [Related]
35. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy.
Lohr F; Hu K; Haroon Z; Samulski TV; Huang Q; Beaty J; Dewhirst MW; Li CY
Mol Ther; 2000 Sep; 2(3):195-203. PubMed ID: 10985949
[TBL] [Abstract][Full Text] [Related]
36. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
[TBL] [Abstract][Full Text] [Related]
38. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
[TBL] [Abstract][Full Text] [Related]
39. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
40. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.
Egilmez NK; Hess SD; Chen FA; Takita H; Conway TF; Bankert RB
Cancer Res; 2002 May; 62(9):2611-7. PubMed ID: 11980657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
